Meet the Docs
CURRICULUM VITAE
Reetu Singh MD, FACE
Dr Vikas
WORK HISTORY
       
SUSSEX PULMONARY AND ENDOCRINE CONSULTANTS, PA
Lewes, DE 19958
  09/2008-present
       
SEACOAST ENDOCRINOLOGY, PA 609 Atlantic Avenue,
Millville, DE 19967
  10/2006 to 08/2008
       
MANSOUR SABERI MD, PA 353 Savannah Rd,
Lewes, DE 19958
  08/2003 to 10/2006
       
ENDOCRINOLOGY ASSOCIATES CCMC Suite 424 One Medical Ctr Blvd,
Upland, PA 19013
  07/2001 to 07/2003
       
       
EDUCATION AND TRAINING
       
MEDICAL SCHOOL DATES DEGREE
All India Institute of Medical Sciences,
Delhi, India
1990- 1995 Medical School - MBBS
       
All India Institute of Medical Sciences,
Delhi, India
01/96-06/96 Ophthalmology Residency
       
       
LICENSURE      
       
Delaware     2003-present
       
Pennsylvania     Inactive
       
       
BOARD CERTIFICATION      
       
American Board of Internal Medicine     1999
       
American Board of Endocrinology   2001
       
       
ACCREDITATION      
       
Thyroid Ultrasound and Ultrasound Guided Thyroid Aspiration
(awarded by AACE-American Association of Clinical Endocrinologists)
  2000
       
ICSD certification for Clinical Densitometrist   2001
       
       
APPOINTMENTS
       
  HOSPITAL  
Attending Physician Beebe Medical Center,
Lewes, DE 19958
08/2003-present
       
Attending Physician Crozer-Chester Medical Center,
Upland, PA
07/2001-07/2003
       
Attending Physician Taylor Hospital
Ridley Park, PA
07/2001-07/2003
       
Attending Physician Sprigfield Hospital
Springfield, PA
07/2001-07/2003
       
       
PUBLICATIONS      
     
Abstracts presented    
  • “Effect of dietary spices on gastrointestinal structure and function in rats”. V. Batra, R.Singh, K.P.Kochar, S.C. Mahapatra. [Ind. J. of Physiol. and Pharmacol. 1992; 36(5)]
    • Annual Conference of the Association of Physiologists and Pharmacologists of India ’92
  • “Effect of long term intake of dietary spices in locomotor activity in rats.” S.C. Mahapatra, V. Batra, R.Singh, M.K. Verma, K.P. Kochar. [Ind. J. of Physiol. and Pharmacol. 1992; 36(5)]
    • Annual Conference of the Association of Physiologists and Pharmacologists of India ’92
  • “Metastatic cervical cancer with ectopic calcitonin production presenting as a thyroid mass”. Reetu Singh, Marluce Bibbo, Mary F. Cunnane, John A. Carlson, Anne E. de Papp.
    • Annual Meeting of American Association of Clinical Endocrinologist, 2001
       
Papers accepted
  • ‘To determine the prevalence of Chronic Suppurative Otitis Media and Deafness in children of a rural community for developing an intervention strategy.” Amit Verma, R.Singh, et al. Ind. J. of Pediatr. 1995; 62: 725-729.
  • “Impact of gender on diabetes mellitus and its associated cardiovascular risk factors”. Reetu Singh MD, Susan Weigers MD, FACC, Barry J. Goldstein MD, PhD. Clinical Geriatrics 9 (7). 63-72,June 2001 2001
  • “Impact of gender on diabetes mellitus and its associated cardiovascular risk factors.” Reetu Singh MD, Susan Weigers MD, FACC, Barry J. Goldstein MD, PhD. Journal of Gender Specific Medicine 2001;4(3):28-36, 2001
  • “Depot-Specific Variation in Protein-Tyrosine Phosphatase Activities in Human Omental and Subcutaneous Adipose Tissue: A Potential Contribution to Differential Insulin Sensitivity”. Xiangdong Wu, Johan Hoffstedt, Wasim Deeb, Reetu Singh, Natalia Sedkova, Assaf Zilbering, Li Zhu, Pauline K. Park, Peter Arner, and Barry J. Goldstein . J Clin Endocrinol Metab 86: 5973-5980, 2001
  • “Metastatic cervical cancer with ectopic calcitonin production presenting as a thyroid mass”. Reetu Singh, Marluce Bibbo, Mary F. Cunnane, John A. Carlson, Anne E. de Papp. Endocrine Practice, Jan/Feb 2002.
       
Chapters Authored
  • “Euthyroid Hyperthyroxinemia” Reetu Singh, Serge Jabbour. Online textbook of E-medicine.
       
Research Activities      
1998-2000: An open-label extension study to assess the long-term safety, tolerability and efficacy of BRL49653C when administered once or twice daily in combination with glyburide to patients with NIDDM – Non insulin dependent diabetes mellitus (112): SmithKline Beecham Pharmaceuticals
   
1999-2000: A phase III, randomized, double-blind, active control trial to evaluate the safety and efficacy of a fixed combination metformin/glyburide product in patients with Type 2 diabetes mellitus who have inadequate glycemic control on maximum dose sulfonylurea monotherapy. (043) Bristol-Myers Squibb, Inc
   
2000-2001: A Multi-Center, Open-Label, Single-Arm Phase IV Trial Evaluating the Diagnostic Utility of Thyrogen® (Thyrotropin alfa for Injection)-Stimulated Thyroglobulin Testing for the Surveillance of Patients with Treated Papillary or Follicular Thyroid Carcinoma at Risk for Recurrence (THYR-006-99) Genzyme
   
1999 A 2-Year, Randomized, Double-Blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone Versus Placebo in Combination with Glipizide in Elderly Patients with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Glipizide Therapy and Who are Intolerant to Metformin or Have a Contraindication to Metformin. (135) SmithKline Beecham Pharmaceuticals
   
1999 A study of inhaled human insulin in subjects with Type 2 DM not optimally controlled with diet and exercise (217-110) Pfizer, Inc
   
1999 Long term safety of inhaled human insulin: extension of therapy in subjects with Type 1 or Type 2 diabetes mellitus completing Phase III randomized treatment trials. (Pfizer 217-111) Pfizer, Inc.
   
1999 A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Glyburide Controlled 12-Month Clinical Evaluation of Oral GI262570 7.5mg Alone, Micronized Glyburide 12mg Alone, or Micronized Glyburide 12mg in Combination with GI262570 (2.5mg, 5mg, or 7.5mg) Administered to Subjects with Type 2 Diabetes Mellitus who are Inadequately Controlled on Maximum Dose Glyburide (Glaxo 30001), Glaxo Wellcome, Inc.
   
1999 A randomized, double-blind study to compare the durability of glucose lowering and preservation of pancreatic beta-cell function of rosiglitazone monotherapy compared to metformin or glyburide/glibenclamide in patients with drug-naïve, recently diagnosed type 2 diabetes mellitus (< 2 years). (SKB 048) SmithKline Beecham Pharmaceuticals.
   
1999 A randomized, double-blind, placebo controlled trial to evaluate the safety and efficacy of rosiglitazone added on to a background of metformin/glyburide tablets in subjects with type 2 diabetes mellitus who have inadequate glycemic control on metformin/glyburide therapy. (BMS 055) Bristol Myers Squibb
   
1999 A double-blind randomized study to evaluate the effects of fixed combination metformin/glipizide therapy in subjects with type 2 diabetes mellitus who have inadequate glycemic control on half-maximum to maximum of the labeled doses of sulfonylurea monotherapy. (BMS 060) Bristol Myers Squibb
   
1999 A Double Blind, Randomized, Placebo Controlled, Multicenter, Two-Year Study of the Effect of the Anti-Glycation Agent, EXO-226 on Renal Dysfunction in Two Strata of Albuminuric Diabetic Patients. Exocell, Inc
   
1999 Comparison of the efficacy and safety of Emitasol™ (Metoclopramide) nasal spray versus placebo in patients with diabetic gastroparesis. (301R) Roberts Laboratories.
   
1999 A multicenter, randomized, double-blinded, parallel group, placebo controlled, clinical evaluation of oral GI262570 sodium tablets (2.5, 5.0. and 7.5 mg GI262570) in combination with current insulin therapy for 26 weeks duration in subjects with Type 2 diabetes mellitus who are inadequately controlled with insulin alone (PPA 30003) Glaxo Wellcome, Inc
   
2000 Dose Finding, Efficacy, Safety, And Pharmacokinetics of AR-H039242XX In Patients With Type 2 Diabetes (AZ 270) Astra Zeneca
   
2001 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (Octave) Bristol Myers Squibb
   
2001 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 52-Week Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of Oral Pyridorin™ (Pyridoxamine Dihydrochloride) In Patients With Type 1 Diabetes And Diabetes-Associated Nephropathy (PYR 204) BioStratum
   
2001 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 52-Week Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of Oral Pyridorin™ (Pyridoxamine Dihydrochloride) In Patients With Type 2 Diabetes And Diabetes-Associated Nephropathy (PYR 203) BioStratum
   
2001 A Randomized, Comparator Controlled, Double-Blind Study of the Liver Safety of Pioglitazone HCl Versus Glyburide With Metformin and Insulin as Part of Step Therapy in Subjects With Type 2 (Non-Insulin Dependent) Diabetes (TAK 506) Takeda Pharmaceuticals
   
   
       
       
 
 
 
  34381 Carpenter's Way
Lewes, DE 19958
© Copyright 2010 Sussex Pulmonary & Endocrine Consultants, PA Tel: 302.644.7201
Fax: 302.644.7218